Bipolar disorder is a serious mood problem that affects emotions and behavior. This study tests a new drug called **ABBV-932** for treating depressive episodes in adults with bipolar disorder (types I or II). Depressive episodes are periods of intense sadness or hopelessness. About 200 adults will take part in the study across 50 locations in the US and Puerto Rico.
Participants will take ABBV-932 capsules for 26 weeks, with a 30-day follow-up to check safety. They will visit the clinic or hospital for regular check-ups, blood tests, and questionnaires. This study might be more demanding than usual care, but it helps understand how well the drug works and its safety.
- The study lasts for 26 weeks, plus a 30-day follow-up.
- Regular visits to clinic/hospital are needed for safety checks.
- Participants must be adults with bipolar I or II disorder.